According to the treatment guidelines, a combination of ACEIs, ARBs, and direct renin inhibitors is not recommended due to the greater risk of hyperkalemia and hypotension and the lack of demonstrated benefit in cardiology trials [29] and diabetic nephropathy trials [30]. This evidence concerns the gene REN and diabetic kidney disease.